Core Viewpoint - The credit rating for Yifeng Pharmacy's convertible bonds remains stable at "AA," with no changes from the previous rating [1]. Group 1 - The previous rating for the convertible bonds was "AA," and the issuer's rating was also "AA," with a stable outlook [1]. - The current rating results for both the issuer and the convertible bonds are unchanged from the last assessment [1]. - The credit rating agency, United Credit Ratings Co., conducted a comprehensive analysis of the company's operational status and industry conditions for this tracking rating [1]. Group 2 - The tracking credit rating report for the convertible bonds can be found on the Shanghai Stock Exchange website [2]. - The announcement is made by the board of directors of Yifeng Pharmacy [3].

Group 1 - The issuer of the convertible bonds is Yifeng Pharmacy Chain Co., Ltd., with a total issuance amount of RMB 1,797.43 million, net proceeds after issuance costs amounting to RMB 1,780.26 million [2][3][14] - The bonds have a maturity period of six years, from March 4, 2024, to March 3, 2030, with a face value of RMB 100 per bond [3][4] - The coupon rates for the bonds are set at 0.30% for the first year, 0.50% for the second year, and 1.00% for the third year [4][5] Group 2 - The initial conversion price for the bonds is set at RMB 39.85 per share, subject to adjustments based on various corporate actions [5][6] - The conversion price will be adjusted to RMB 32.79 per share effective from June 7, 2024, due to the company's annual profit distribution [7][8] - Further adjustments will reduce the conversion price to RMB 32.54 per share effective from October 15, 2024, and to RMB 32.14 per share effective from June 18, 2025 [8][19] Group 3 - The total amount raised from the bond issuance will be used for projects including the construction of pharmaceutical warehouses in Jiangsu, Hubei, and Hebei, with a total investment of RMB 2,534.33 million [14][15] - The bonds are rated AA by a credit rating agency, with a stable outlook, and the issuer's credit rating is also maintained at AA [16][17] - The bonds will not be secured, and the management of the raised funds will be conducted in a designated special account [15][16] Group 4 - The actual controller and major shareholders have reduced their holdings of the convertible bonds, with a total of 5,259,730 bonds sold, representing 29.26% of the total issuance [20][21] - The company has also repurchased and canceled a portion of restricted stock from its 2022 incentive plan, which does not affect the conversion price of the bonds [21][22] - The company will continue to monitor the impact of these actions on its operational performance and debt repayment capabilities [22]

Core Viewpoint - Yifeng Pharmacy (603939) announced that Huxin Chuangtou, Yizhi Feng, and Yiren Tang plan to collectively reduce their holdings by no more than 2% of the company's shares [1] Group 1 - The total planned reduction in shareholding is capped at 2% [1]

Core Viewpoint - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of its 2024 annual equity distribution plan, resulting in a decrease from 32.54 CNY to 32.14 CNY per share [1][3]. Group 1: Bond Information - The convertible bond, referred to as "益丰转债," was publicly issued on March 4, 2024, and listed on the Shanghai Stock Exchange on March 27, 2024 [1]. - The bond has a maturity period of 6 years, from March 4, 2024, to March 3, 2030, with a conversion period from September 8, 2024, to March 3, 2030 [1]. Group 2: Equity Distribution Details - The company plans to distribute a cash dividend of 0.40 CNY per share (including tax) to all shareholders, with the record date set for June 17, 2025, and the ex-dividend date on June 18, 2025 [2]. - The adjustment to the conversion price is based on the company's equity distribution plan, which includes provisions for adjusting the conversion price in the event of cash dividends, stock dividends, or other equity changes [2]. Group 3: Conversion Price Adjustment - The conversion price adjustment formula is specified in the company's prospectus, detailing how the price will be recalculated based on various equity distribution scenarios [2]. - The adjusted conversion price of 32.14 CNY per share will take effect on June 18, 2025, following the equity distribution [3]. - The convertible bonds will be suspended from conversion from June 11, 2025, to June 17, 2025, and will resume conversion on June 18, 2025 [3].

Key Points - The company announced a cash dividend of 0.40 CNY per share for A shares [1][2] - The dividend distribution was approved at the annual shareholders' meeting on May 29, 2025 [1] - The total cash dividend to be distributed amounts to approximately 484.97 million CNY based on the total share capital of 1,212,416,854 shares [1][2] Relevant Dates - The record date for the dividend is June 17, 2025, with the ex-dividend date on June 18, 2025, and the payment date also on June 18, 2025 [2][3] Distribution Implementation - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [2] - The distribution does not involve the issuance of bonus shares or capital increase [2] Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.40 CNY per share [3][4] - For shares held for less than one year, the tax rate varies based on the holding period, with a maximum effective tax rate of 20% for shares held for one month or less [3][4] - For Hong Kong investors, the net cash dividend after a 10% withholding tax will be 0.36 CNY per share [4]

Group 1 - The company held its fourth meeting of the fourth Supervisory Board, which was convened by the chairperson Meng Peng, with all three supervisors present, complying with relevant laws and regulations [1] - The Supervisory Board approved the proposal to conclude certain fundraising projects and permanently supplement working capital with the remaining funds, which is seen as a reasonable decision to enhance the efficiency of fund usage and beneficial for the company's long-term development [1][2] - The proposal regarding the cancellation of unvested restricted stock due to the departure of two incentive targets and the failure to meet performance targets for the 2024 fiscal year was discussed, resulting in a total of 1.63205 million shares being rendered invalid [2][3] Group 2 - The voting results for the proposal to conclude fundraising projects showed unanimous support with 3 votes in favor, while the proposal regarding the cancellation of restricted stock could not be resolved due to insufficient non-related supervisors present to form a quorum [2][3] - The company plans to disclose further details regarding the cancellation of restricted stock on the official information platform [2][3]

Group 1 - The annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. was held on May 29, 2025, in Changsha, Hunan Province [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, with a total of 9 directors and 3 supervisors present [3] Group 2 - All proposed resolutions were approved during the meeting, including the annual work reports of the board and supervisory committee, financial statements, and profit distribution plan for 2024 [4][5][6] - The meeting authorized the board to formulate a mid-term dividend plan and approved the appointment of an accounting firm for 2025 [5][6] - A significant resolution regarding the company's shareholder return plan for the next three years (2025-2027) was also passed [6] Group 3 - The meeting was witnessed by lawyers from Hunan Qiyuan Law Firm, confirming that the meeting's procedures and voting results were legally valid [6]

Core Viewpoint - The company, Yifeng Pharmacy Chain Co., Ltd., is set to hold an annual performance briefing for 2024 and the first quarter of 2025 on June 3, 2025, to provide insights into its operational results and financial status [2][3][4]. Group 1: Performance Briefing Details - The performance briefing will take place on June 3, 2025, from 15:00 to 16:00 [4]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will utilize video and online interaction for communication [4][5]. - Investors can submit questions for the briefing from May 27 to June 2, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Management Participation - Key participants in the briefing will include the Chairman and CEO, Mr. Gao Yi, the Financial Officer, Mr. Wang Yonghui, the Board Secretary, Mr. Fan Wei, and the Independent Director, Mr. Huang Chunan [4]. Group 3: Shareholding and Reduction Plan - Prior to the reduction plan, the Executive President, Mr. Gao Youcheng, held 201,600 shares, representing 0.0166% of the total share capital, while the Assistant President, Mr. Yan Jun, held 99,600 shares, representing 0.0082% [8]. - The reduction plan was disclosed on January 24, 2025, with a maximum reduction of 75,300 shares planned, which was successfully executed within the specified timeframe [9][10].

证券代码：603883 证券简称：老百姓 公告编号：2025-007 老百姓大药房连锁股份有限公司 第五届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于2025年4月3日发出召开第五届董事会第八次会议 的通知，会议于2025年4月11日在公司会议室以通讯方式召开，本次董事会应参加表决的董事9名，实际 参加表决的董事9名。本次会议由董事长谢子龙先生主持，董事会秘书等相关人员列席会议。 二、董事会会议审议情况 （一）审议通过《关于公司高管离任的议案》 本议案已经公司第五届董事会提名、薪酬与考核委员会第四次会议审议通过。 为深化组织改革，经公司与江宇飞先生友好协商，江宇飞先生不再担任公司副总裁职务，离任后将不再 担任公司任何职务。 表决结果：同意9票，反对0票，弃权0票，表决通过。 具体内容详见公司在上海证券交易所网站（http://www.sse.com.cn）同日披露的《关于公司高管离任的 公告》。 特此公告。 老百姓大药房连锁 ...

公司于2025年4月1日获悉公司控股股东医药集团所持有公司的部分股份已办理解除质押，现将相关情况 公告如下： 一、本次股份解除质押的具体情况 2023年医药集团将其持有的7,600,000股股票质押给中银国际证券股份有限公司，具体内容详见公司于 2023年6月2日在上海证券交易所网站（www.sse.com.cn）披露的《关于控股股东股份质押的公告》（公 告编号：2023-026）。 证券代码：603883 证券简称：老百姓 公告编号：2025-006 老百姓大药房连锁股份有限公司关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告日，老百姓大药房连锁股份有限公司（以下简称"公司"）控股股东老百姓医药集团有限公 司（以下简称"医药集团"）持有公司股份198,564,175股，占公司股份总数的26.12%，本次解除股份质押 10,680,000股后，医药集团持有公司股份累计质押数量为138,324,000股，占其持股总数的69.66%，占公 司总股本的18.20%。控股 ...